Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Before you risk a nickel on this volatile biotech stock, you should know that sales of Casgevy haven't gotten off the ground yet. The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: ...
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
In a report released today, William Pickering from Bernstein maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback